CVS Caremark GLP-1 Coverage for Weight Loss (2026)
If your prescription card says CVS Caremark, you have probably had a confusing stretch. Maybe your GLP-1 medication was covered, then suddenly was not. Maybe your pharmacy told you the preferred drug changed, then changed back. Maybe you are just trying to figure out, before you start, whether your plan will pay for a GLP-1 at all.
That confusion has a specific explanation. Here is what CVS Health and CVS Caremark’s own published documents say as of 2026-10-16, what changed in July 2025 and October 2026, and how to find out where your own plan stands.
Transformation Health is an independent guide, not a provider, and is not affiliated with CVS Caremark or CVS Health: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
First, what CVS Caremark actually is
CVS Caremark is not your insurance company. It is a pharmacy benefit manager, or PBM, and part of CVS Health.[3] A PBM manages the prescription drug side of a health plan for whoever sponsors that plan, usually an employer or a health insurer. It maintains the formulary, the list of covered medications and their cost tiers, and runs the prior authorization process when you fill a prescription.
Caremark runs the pharmacy benefit for many employers and health plans, including Aetna, whose formulary documents say its pharmacy benefits are administered through an affiliated pharmacy benefits manager, CVS Caremark.[2] If you have an Aetna plan, our guide to Aetna GLP-1 coverage covers Aetna’s own rules and criteria.
That structure matters for two reasons. First, your employer or plan sponsor decides whether weight management medications are covered at all. Second, for plans that do cover the category, Caremark sets which drugs are preferred on its template formularies, and plan sponsors can customize those formularies.[3]
The short answer
Coverage depends on your plan, not on Caremark alone. As of 2026-10-16, the October 2026 CVS Caremark Performance Drug List - Standard Control lists Wegovy, Wegovy HD, Zepbound, and Foundayo in its antiobesity category, alongside generic liraglutide, orlistat, phentermine-topiramate, and Qsymia.[5] The same document says your specific plan design “may not cover certain medications, products or categories, regardless of their appearance in this document."[5]
In other words, the weight loss drugs are on Caremark’s list, and your employer or health plan decides whether the list applies to you for weight loss. CVS Health’s own announcement says the Zepbound change applies “for plan sponsors who elect to provide coverage” of these medications.[3] So the real question is not “does CVS Caremark cover GLP-1s,” it is “does my plan include weight loss medications.”
GLP-1 medications prescribed for type 2 diabetes are a separate coverage category, with their own criteria. This page is about coverage for weight management.
What Caremark’s published documents say
These rows come from CVS Health announcements and from plan sponsor copies of the CVS Caremark Performance Drug List - Standard Control for Clients with Advanced Control Specialty Formulary, dated January 2026 and October 2026. Caremark has other template formularies, and your plan may use a different list or a customized one, so treat this as a starting point.
| Question | What CVS Health and CVS Caremark documents say (as of 2026-10-16) |
|---|---|
| Are weight loss drugs covered on every plan? | No. Plan sponsors elect whether to cover them,[3] and the drug list says plan design may not cover certain categories[5] |
| Wegovy | Preferred antiobesity drug on the January 2026 and October 2026 Standard Control lists[4][5]; Wegovy HD added on the October 2026 list[5] |
| Zepbound | Removed from Caremark’s commercial template formularies July 1, 2025[1]; on the January 2026 list’s formulary removals[4]; added back as an additional preferred option October 1, 2026[3][5] |
| Foundayo (orforglipron), oral | New-to-market block removed June 1, 2026, where approved by plans[3]; preferred antiobesity drug on the October 2026 list[5] |
| Saxenda | Listed as a preferred antiobesity drug on the January 2026 list[4]; the October 2026 list names generic liraglutide in that category instead[5] |
| Prior authorization | Caremark publishes PA criteria documents for Wegovy and tirzepatide (Zepbound)[6][7] |
Your plan sets your share of the cost for each drug. The drug list says plans may have different cost sharing for specific products and may vary cost sharing by the condition being treated.[5]
Prior authorization criteria. As of 2026-10-16, Caremark’s published criteria documents for Wegovy (4774-C) and for tirzepatide (6947-C, the “FE Compatible” version) list these adult criteria for weight management:[6][7]
| Criterion | What Caremark’s PA documents say (as of 2026-10-16) |
|---|---|
| Age | Adult (Wegovy: 18 or older) |
| Lifestyle documentation | At least 6 months in a comprehensive weight management program (behavioral changes, reduced-calorie diet, more physical activity, with continuing follow-up) before starting drug therapy |
| BMI criteria | Baseline BMI of 30 or higher, or 27 or higher with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or dyslipidemia) |
| First approval | 8 months |
| Renewal requirement | At least 3 months at a stable maintenance dose, and a loss of at least 5 percent of baseline body weight or keeping that initial 5 percent off; renewals are approved for 12 months |
Your plan may use a different criteria document. Ask member services which one applies to you.
Other FDA-approved uses. Wegovy is also FDA-approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity.[8][9] Caremark’s PA documents include separate criteria for these uses; for Zepbound and sleep apnea, they require a sleep study showing at least 15 events per hour and a current BMI of 30 or higher.[6][7] Ask your plan whether these uses are reviewed separately from weight loss, and ask your prescriber whether either fits your situation.
CVS Weight Management. In a June 27, 2025 article, CVS Health described CVS Weight Management as a program offered to CVS Caremark clients, meaning employers and plans, that pairs GLP-1 medications with lifestyle clinical support.[1] Whether you have it depends on your employer or plan. If your benefits materials mention it, ask how it affects your GLP-1 coverage.
What changed in 2025 and 2026
July 1, 2025. CVS Caremark took what CVS Health called “a formulary action to prefer Wegovy and remove Zepbound” on its commercial template formularies.[1] CVS Health said members with an active Zepbound prior authorization would not need a new one to move to Wegovy, and that members who had severe or intolerable side effects or insufficient weight loss on Wegovy could request a formulary exception, reviewed case by case with supporting documentation from their provider.[1]
January 2026. The January 2026 Standard Control list named orlistat, Qsymia, Saxenda, and Wegovy as the preferred antiobesity drugs and listed Zepbound among its formulary removals.[4]
May 28, 2026. CVS Health announced that Caremark would remove the new-to-market block on Foundayo effective June 1, 2026, and add Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026, for plan sponsors that elect to cover these medications. It said plan sponsors that adopt Caremark template formularies “retain discretion to customize coverage."[3]
October 1, 2026. The October 2026 Standard Control list took effect. It lists Foundayo, Qsymia, Wegovy, Wegovy HD, and Zepbound as preferred antiobesity brand drugs.[5]
The pattern to take away: formulary status is not permanent, and none of these changes had anything to do with any individual member’s health. Employers also revisit their own plan decisions every plan year. A medication covered today can be removed next year, and the reverse, so a benefit you have now is worth confirming again at open enrollment. For how other pharmacy benefit managers handle these drugs, see our pages on Optum Rx and Express Scripts.
Medicare and individual plans
Medicare Part D. Plans with Medicare drug coverage follow federal Part D rules, whichever company manages the pharmacy benefit. The law lets Part D exclude “agents when used for anorexia, weight loss, or weight gain,” so a GLP-1 prescribed for weight loss alone is generally not covered under basic Part D coverage.[10] Part D plans may cover a GLP-1 for another FDA-approved use, such as type 2 diabetes, and federal rules let plans offering enhanced alternative coverage add supplemental drug benefits.[11] Separately, CMS is running the Medicare GLP-1 Bridge, a demonstration from July 1, 2026 through December 31, 2027 that gives eligible Part D enrollees access to certain GLP-1 drugs for weight management outside the regular Part D benefit.[12] Ask your plan, and ask CMS or 1-800-MEDICARE whether the Bridge applies to you. Our pages on Medicare Part D and GLP-1 coverage and the Medicare GLP-1 Bridge cover the details.
Medicaid. If Caremark manages a state Medicaid pharmacy benefit, the state sets the coverage rules. Our page on the BALANCE model and state Medicaid explains how state coverage works.
Individual and marketplace plans. Coverage depends on the plan you bought. The plan documents, not the PBM name on the card, decide whether weight loss drugs are included.
How to check your own plan in ten minutes
You do not need to guess, and you do not need to wait for a denial letter. Three routes, fastest first:
Ask your HR benefits team. If you have an employer plan, the single decisive fact is whether your plan includes weight loss medication coverage. HR or your benefits portal can answer that directly, and they can tell you which Caremark formulary your plan uses and whether it is customized.
Call the number on your prescription card. Ask three questions. Does my plan include coverage for weight loss medications? If so, which GLP-1 medications are on my formulary for weight management, including Zepbound and Foundayo after the October 1, 2026 update? And which prior authorization criteria apply to my plan?
Check your plan summary. Caremark’s drug lists direct members to sign in or register at Caremark.com and click Plan Summary on the Plan and Benefits menu for plan-specific coverage and cost sharing.[5] Search for semaglutide, tirzepatide, or orforglipron, and read the indication notes carefully; a listing under diabetes coverage does not mean weight management is covered.
If the benefit exists on your plan, your next step is the paperwork. Our guide to GLP-1 prior authorization walks through the documentation these requests usually need, including the BMI record and the 6 months of weight management program participation that Caremark’s criteria ask for.
If your plan says no
Plenty of people with Caremark cards land here, through no fault of their own. What you do next depends on why the answer was no.
The denial was about criteria or documentation. This is often fixable. A documented baseline BMI, weight-related conditions noted explicitly in your chart, and recorded participation in a weight management program for at least 6 months address the criteria above. HealthCare.gov says you generally have 180 days from a denial notice to file an internal appeal, and if that appeal is denied, you can in many cases ask for an independent external review.[13][14] Start with our guide on what to do when insurance denies your GLP-1.
The medication you want is not on your formulary. Ask your plan how to request a formulary exception. Your prescriber’s documentation of why the formulary alternative is not appropriate for you is what carries the request. For individual and small-group plans that must cover essential health benefits, federal rules require an exception process, with a decision due within 72 hours on a standard request and within 24 hours when circumstances are urgent.[15] Employer plans follow different federal claim rules, and your plan documents state the exact limits that apply to you.
Your plan does not include the benefit. An appeal generally cannot override a plan exclusion, and no Caremark formulary update adds a benefit your plan sponsor did not choose. You can ask HR whether weight loss coverage is under consideration for the next plan year, check whether another plan at open enrollment includes it, and ask your prescriber whether any other covered use applies to you. Beyond that, the options are outside insurance:
- Manufacturer savings and self-pay options. Novo Nordisk and Eli Lilly each publish savings and self-pay terms, and the terms change. Our page on GLP-1 savings programs compares them.
- Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[16] Our page on compounded GLP-1 without insurance explains how that route works.
Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. The full insurance coverage overview can help you weigh the options side by side.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] CVS Health. “Improving access and affordability to high-cost weight management drugs” (CVS Health PBM news), June 27, 2025. Accessed 2026-10-16. https://www.cvshealth.com/news/pbm/improving-access-and-affordability-to-high-cost-weight-management-drugs
[2] Aetna. “Formulary Updates for Aetna Standard Plan effective October 1, 2026.” Accessed 2026-10-16. https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/individuals-families-health-insurance/document-library/pharmacy/SOC-for-10.01.26-Aetna-Standard-Plan.pdf
[3] CVS Health. “CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options” (company news release), May 28, 2026. Accessed 2026-10-16. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
[4] CVS Caremark. “Performance Drug List - Standard Control for Clients with Advanced Control Specialty Formulary,” January 2026 (plan sponsor copy). Accessed 2026-10-16. https://myteamcare.org/-/media/TeamCare/Files/Forms-and-Documents/Members/Prescription/2026-january-standard-control-formulary.pdf
[5] CVS Caremark. “Performance Drug List - Standard Control for Clients with Advanced Control Specialty Formulary,” October 2026 (plan sponsor copy). Accessed 2026-10-16. https://pearsonbenefitsus.com/wp-content/uploads/2026/08/CVS-Caremark-Formulary_Oct-2026.pdf
[6] CVS Caremark. “Wegovy PA with Limit 4774-C P08-2025 v5” (initial prior authorization with quantity limit, weight loss management). Accessed 2026-10-16. https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa_forms_default/4774-C_Wegovy.pdf
[7] CVS Caremark. “Tirzepatide PA with Limit FE Compatible 6947-C P08-2025 v4” (initial prior authorization with quantity limit, weight loss management). Accessed 2026-10-16. https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa_forms_default/6947-C_Zepbound.pdf
[8] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Novo Nordisk. Revised 06/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[9] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly and Company. Highlights revised 08/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[10] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions). Accessed 2026-10-16. https://www.law.cornell.edu/uscode/text/42/1395w-102
[11] 42 CFR 423.104(f)(1) (enhanced alternative coverage; supplemental benefits). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/42/423.104
[12] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
[13] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
[14] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
[15] 45 CFR 156.122(c) (prescription drug benefits: standard and expedited exception requests). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/45/156.122
[16] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important disclosures
Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. It does not represent the terms of your specific plan and is not legal advice. Plan sponsors can customize Caremark’s template formularies. Confirm current benefits, formulary status, and prior authorization requirements directly with your insurance company or pharmacy benefit manager: call the member services number on your insurance or prescription card, or ask your HR benefits team if you have an employer plan.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy and Saxenda are trademarks of Novo Nordisk A/S. Zepbound, Mounjaro, and Foundayo are trademarks of Eli Lilly and Company. CVS Caremark, CVS Health, CVS Weight Management, Aetna, and Qsymia are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by CVS Caremark, CVS Health, Aetna, Novo Nordisk, or Eli Lilly. Transformation Health does not accept payment from providers. How we make money.